Aim: The aim of the study is to investigate quality oflife (QoL) in the context of a multinational trial. The questions addressed are: is the Rotterdam Symptom Checklist (RSCL) 1) feasible and 2) reliable in cross cultural reearch, 3) is earlier validation confirmed in a multinational trial and 4) are there systematic differences in QoL accross cultures?
Introduction
The importance of cross-cultural comparison in QoL assessment has been stressed recently [1] [2] [3] [4] [5] . Multinational collaboration in medical research necessitates both the availability of instruments that are validated internationally as well as insight in the existence of crosscultural differences. During the past decades several instruments have been devised for measurement of QoL in cancer patients. Some of these are meant to measure QoL of cancer patients in general, such as the CARES [6] , EORTC QLQ [7] , the FACT [8] , and the FLIC [9] . Others have been developed for specific cancer patient populations, such as the Breast Cancer Questionnaire devised by Levine et al. [10] . Some of these instruments have been used in different countries, but little evidence regarding differences between countries or cultures has been published.
One of the instruments for QoL measurement in cancer patients is the Rotterdam Symptom Checklist (RSCL). This instrument was originally developed to measure QoL as reported by patients participating in clinical trials. Later, it proved to be useful as a tool to study the impact of psychosocial interventions in cancer patients [11] and to detect the presence of psychiatric illness [12, 13] . The RSCL was constructed on the basis of secondary analyses of data from different studies using the Hopkins Symptom Checklist [14] , an ad hoc symptom checklist used in a breast cancer patient population [15] and the Symptom Distress scale developed by McCorkle and Young [16] . On the basis of a first validation study, a checklist was constructed including a list of 30 symptoms relating to the perceived level of physical and psychological distress and a list of eight items referring to activities of daily living [17] . Further validation studies have substantiated both the reliability of the RSCL and the structure of the symptom checklist in the Netherlands, Italy, the UK and Spain [11, [17] [18] [19] . The psychological distress scale of the RSCL was shown to be related to depression and anxiety assessed with other instruments, such as the HADS and STAI and therefore has concurrent validity [11, 12, 18] . Clinical validity of the instrument was substantiated as it proved to distinguish between disease states [20] , different che-motherapy regimens [21] , and anti-emetic treatments [22] . On the basis of its feasibility and validity, the use of the RSCL was advocated in clinical research [23] as well as cost-effectiveness analyses [24] .
Although the RSCL has proved to be a useful instrument in different cultures, testing of its feasibility, reliability and validity did not take place in the context of an international clinical trial. As a homogeneous study sample is involved, such a study allows for testing whether results are comparable across different countries. In the beginning of 1992, the Early Breast Cancer Trialists' Collaborative Group has presented an overview of systemic treatment in early breast cancer [25, 26] . Following their report it has been suggested that ovarian ablation should now be "seriously considered as an alternative to adjuvant chemotherapy" [27] . In the randomised trial reported from here, the efficacy of ovarian ablation by hormonal treatment, a LHRH analogue (Zoladex, Goserlin), and standard chemotherapy (CMF), are compared as adjuvant therapy in the management of node positive stage II breast cancer in pre-/ perimenopausal women aged 50 years or less. The two treatment groups will be compared with regard to disease free survival, overall survival and side effects. Since the treatments are likely to have different effects on patients' well-being, it was decided to measure QoL as a separate endpoint.
The aim of the present study is to investigate, in the context of this multinational trial, whether the RSCL is 1) feasible and 2) reliable in a cross-cultural setting, 3) whether earlier validation is confirmed in a cross-cultural setting and 4) whether systematic differences in QoL scores exist accross cultures. Since all patients involved in an international study fulfill the established eligibility criteria, they are experiencing a similar situation and therefore considered to be an ideal sample for cross cultural comparison. after primary surgery and before the start of adjuvant therapy. The second assessment took place at three months after baseline which coincides with the end of the first three cycles of chemotherapy. Patients were asked to complete the questionnaire in the outpatient clinic and were given an envelope. To assure confidentiality it was returned in this (closed) envelope to the treating clinician. He/she sent it along with other trial forms to the central data collection office.
Patients and methods

Measuring instrument
The RSCL covers patients' experiences of physical and psychological symptoms, the activity level and a global evaluation of life quality. The latter question was added for conceptual reasons after the initial construction of the instrument. It has proven discriminant validity in cancer patients [28J. Two symptoms which were expected to be relevant for hormonal treatment: hot flushes and weight changes, were added to the symptom list. Since no short instrument was available to cover social function, three ad hoc questions were constructed [29] . However, data regarding the social impact scale are not elaborated in this paper, since these are not considered part of the standard RSCL. The resulting questionnaire was translated into all relevant languages using the forward and backward translation procedure.
Sample
Consecutive pre-/peri-menopausal patients, aged <51 years, with histologically confirmed stage II, node positive breast cancer and a tumour of 5 cm or less were recruited for the trial after informed consent. Exclusion criteria are: evidence of distant metaslases, previous systemic therapy for breast cancer, oophorectomy or radiotherapy to the ovaries, and currently being pregnant or breast-feeding. The patients being treated originate from 14 different countries. Thirteen countries are of relevance for QoL measurement (see Table 1 ).
For cross-cultural comparison, clusters of language/culture background are formed based on the countries involved. Subsamples are to involve a minimum of 50 respondents.
Data collection
The QoL questionnaire was planned to be administered six times over a three-year period. The first two measurements are reported in this paper. The first assessment was planned at randomisation immediately
Statistical analysis
We have chosen to investigate psychometric properties of the QoL measuring instrument used before the end of the patient recruitment period and thus separate clearly psychometric data analysis and the analysis of treatment effectiveness.
The homogeneity within each cultural cluster was investigated by a muhivariate comparison of QoL scores between the corresponding countries using one-way MANOVA.
For descriptive purposes, means and standard deviations were calculated for quantitative variables, and absolute and relative frequencies for qualitative variables.
The results of the different QoL scales are represented as summary scores over the corresponding items. To make the scoring of scales with different numbers of items and/or answering categories comparable, all scales have been standardized to a range of 0 to 100, with 0 representing the best possible and 100 the worst possible condition.
Feasibility of the QoL questionnaire was investigated by calculating the rate of completed questionnaires over time and the rate of nonmissing answers for items from the completed questionnaires.
The reliability of the multi-item scales was estimated by means of the coefficient of internal consistency (Cronbach's a) for baseline data and the three month evaluation for the whole sample as well as the different cultures separately. As recommended by Nunnally [30] an estimate of percentage of at least 0.70 was considered to indicate adequate reliability of a scale, given the comparative purpose of the study.
Confirmation of validity was examined by investigating whether the two factor structure established earlier was found at baseline [17] . Due to the limitation of available sample sizes per country, the factor analysis could not be replicated for each individual culture.
To establish whether cultural differences are relevant, QoL scores at baseline were investigated by using methods of analysis of variance (ANOVA). Differences in change of QoL scores from baseline to the second measurement point were analysed adjusted for baseline scores by analysis of covariance (ANCOVA).
For all tests a P-value of 0.05 was considered to indicate statistical significance. However, the interpretation of the results should take into account the number of QoL indicators that had to be studied and tested.
All data storage and analysis was performed using the Statistical Analysis System [31] .
Results
Sample
Eleven thousand .one-hundred and one patients were recruited in the trial at the time of data analysis. Of these 44 (4%) were randomized recently and therefore their data were not available for analysis yet. All Italian centres and some of the German centres involved did not participate in the QoL study. 170 patients (15.4%) were recruited from these non-participating centres or were randomized before the QoL data collection was started. Of the remaining 887 patients, 689 (78%) completed the first QoL questionnaire. The background characteristics of the study sample are presented in Table 1 .
Three months after randomisation, given the time lag involved, 802 patients should have completed the second questionnaire. Data of 544 (68%) were available for analysis. 519 patients (65%) filled in the first as well as the second questionnaire.
The sample was divided in six subsamples: 1) an eastern European sample involving Hungary, Czechia and Slovakia (n = 152), 2) an English-speaking cluster involving Australia, Ireland and the UK (n = 115), 3) a Finnish sample (n = 62), 4) a French-speaking cluster involving France and Belgium (n = 86), 5) the German sample (n = 178), and 6) a 'Latin' cluster involving Argentina, Portugal and Spain (n = 96). No significant differences were found within the eastern European, the English-speaking and the French cluster. Heterogeneity, however, was found in the Latin cluster. Patients from Spain differed from the ones from Argentina and Portugal with respect to QoL at baseline. Therefore, the results regarding this cluster have to be considered more cautiously.
Feasibility
To establish feasibility, the rate of completion was considered first. Of the 14 countries participating in the current trial, 13 were involved in the QoL data collection. The non-involvement of one country and several individual centres has resulted in a loss of 15.4% of patients for the QoL data collection. Of the patients from the centres and countries involved, 78% completed the first questionnaire. The second QoL questionnaire was completed by 68% of these patients.
Second, the completeness of the questionnaires was examined. The proportion of missing answers for the different items is presented in Table 2 . At baseline, in five out of 41 items (12.2%) the percentage of missing answers is exceeding 2.5%. At the second measurement this was the case for three questions (7.3%). Answers to the questions regarding decreased sexual interest (5.1%/-), going to work (11.3%/8.5%) and overall quality of life (5.2%/ 3.8%) were missing most often.
Reliability
Reliability was investigated both for the whole study sample and for the different cultures separately. Results are presented in Table 3 . As can be read from this table, the reliabilities for the physical distress scale range from 0.68 to 0.85 for the baseline, and from 0.77 to 0.85 for the three month measurement. For the activity scale the reliability ranges from 0.57 to 0.80 for the first, and from 0.41 to 0.89 for the second measurement. The reliability of the psychological subscale ranges from 0.83 to 0.89 for the first, and from 0.85 to 0.90 for the second measurement. subscale. In the present factor analysis these eight symptoms were again part of the first factor. Three other symptoms load, although less strongly, on the first factor: sleeping problems, decreased sexual interest and lack of appetite. All other 19 symptoms have a higher factor loading on the second factor, as in the earlier analysis.
Cross-cultural comparison
The comparison of QoL results cross-culturally is displayed in Table 5 .
Significant differences between cultures were observed for all QoL indicators: physical distress, psychological distress, global QoL (all with P < 0.0001) and activity level (/> = 0.0028). This finding indicates that patients enter the trial on different distress levels depending on their cultural origin. For three out of four indicators (activity level, psychological distress and overall QoL) the level of change from baseline to three months was also different across cultures (P < 0.01 in all three).
Discussion
Recently, the importance of international comparison of QoL data has been raised regularly. Few studies have made such comparisons directly in the context of a clinical trial. In the study reported here, the sample " Only factor loadings of 0.33 or higher are reported.
investigated is homogeneous with respect to disease characteristics and treatment phase. It is therefore an ideal sample to make such comparisons and, at the same time, compare the validity of a QoL instrument across cultures.
The feasibility of the QoL assessment proved to be satisfactory. Response rates were adequate for the baseline as well as the three months measurement. Also, completeness within the questionnaire was adequate. Interestingly, the number of missing data was lower for the second measurement. Patients, in other words, may learn to fill in the questionnaire. Sadura et al. [32] have reported good data collection in a national clinical trial. On the basis of our data, it can be concluded that quality of life assessment is feasible also in an international clinical trial.
The reliability of the RSCL physical and psychological distress subscales was good cross-culturally: out of 28 coefficients only one did not reach the 0.70 level at first measurement. Moreover, for the second assessment all but one reach the 0.80 level. Results regarding the activity subscale were satisfactory in some cultures but not in others. Inspection of the data made it clear that for some items there was very little or no variability in the activity scale in some cultures. The lower range of the activity scale did not discriminate in rather healthy populations: patients in these samples were all able to care for themselves without help or difficulty. In those instances internal consistency, which is based on the covariance of items, is a priori expected to be low.
The two-factor structure proposed earlier for the RSCL was replicated in the baseline measurement [17] . The psychological and the physical factor were clearly present, as they were before. The seven psychological symptoms essentially formed the psychological distress subscale. Difficulty sleeping was now also part of this scale. This symptom, as in earlier studies, lies between the psychological and physical domain. Its most salient background is likely to depend on the actual disease or treatment state of patients. Lack of appetite, energy and sexual interest loaded almost equally on both factors. On the basis of these results, the subdivision in a physical and a psychological distress scale is maintained as proposed earlier.
Taken things together, it can be concluded that the psychometric properties of the RSCL are substantiated in the context of an international clinical trial.
Although cross-cultural QoL research has gained increased attention over recent years, few studies have actually investigated cultural differences [33] . A smaller study found differences among cancer patients from different countries [34] , another found differences between epilepsy patients from three countries [35] . An important finding from the present larger scale study is that there are clear differences between cultures in QoL. Differences were evident for all different QoL indicators assessed at baseline. Also, the change over time was not consistent in all cultures. These findings are not easy to explain. Guillemin et al. [4] indicate that differences found when using a questionnaire cross-culturally may result from either a semantic, an idiomatic, an experiential or a conceptual distinction. For the present study, the RSCL was translated according to the standard forward and backward translation procedure. Differences of opinion regarding the translation were discussed by a bilingual panel. However, in the final translations in one or another language there may be subtle linguistic differences. In a semantic or idiomatic sense the translated instruments may therefore depart from the original one to some extent. Also, the distance between the scale points may be perceived differently in different cultures. However, the latter explanation is less likely to be valid. The differences found are quite constant over the scales used in the questionnaire, even though these do not always have the same answering categories. Thus, experiential differences may account for the results obtained. For example, the finnish sample systematically had the most positive results regarding most of the indicators studied. Likewise, the french subsample was found to have a lower QoL almost consistently across domains. How experiential differences can be explained is unsure so far. For example, one might expect patients from one culture to be more extravert than patients from another culture. More extravert patients are likely to be more easily inclined to express negative physical, psychological or social experiences. Also, the way information is conveyed to patients and, as a result, adjustment to illness, might be different in the cultures involved. These explanations are, however, speculative. More theoretically oriented studies are necessary to clarify these issues.
The different changes that occur from baseline to the three month assessment may in part be explained also by the phenomenon of 'regression to the mean'. For example, the finnish sample was the only one that worsened in terms of overall QoL. This sample turned out to have the best overall QoL at baseline. The german sample, on the other hand, improved most clearly from baseline but was most negative about the overall QoL at the first assessment. Further data collection is needed to gain insight in the patterns of change in both the sample at large and the different subsamples.
So far, as baseline QoL as well as changes of QoL differ across cultures, it has to be concluded that treatment results regarding QoL can not automatically be generalised cross-culturally. This result might have important implications for QoL assessment in international trials. If replicated, it implies that cultural background should be taken as a covariate in such studies. Also, it implies that conclusions from QoL studies can not immediately be transposed from one country to another. Further work will have to be done before we understand these results and comprehend how disease and treatment affect QoL differentially across cultures and countries.
